AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca announces a $3.5 billion capital investment in the United States to expand its research and manufacturing footprint by 2026. The investment includes $2 billion of new funding that will create over 1,000 high-skilled jobs. The expansion encompasses a new R&D centre in Cambridge, Massachusetts, biologics manufacturing in Maryland, cell therapy facilities on both coasts, and specialty manufacturing in Texas. This investment is part of AstraZeneca's strategy to achieve $80 billion in Total Revenue by 2030. The US currently represents 44% of AstraZeneca's Total Revenue, making it the company's largest market with 17,800 employees across 17 sites in 12 states.
AstraZeneca annuncia un investimento di capitale di 3,5 miliardi di dollari negli Stati Uniti per espandere la sua presenza nella ricerca e nella produzione entro il 2026. L'investimento include 2 miliardi di dollari di nuovi fondi che creeranno oltre 1.000 posti di lavoro altamente qualificati. L'espansione prevede un nuovo centro R&S a Cambridge, Massachusetts, la produzione di biologici nel Maryland, strutture per la terapia cellulare su entrambe le coste e produzione specializzata in Texas. Questo investimento fa parte della strategia di AstraZeneca per raggiungere un fatturato totale di 80 miliardi di dollari entro il 2030. Gli Stati Uniti attualmente rappresentano il 44% del fatturato totale di AstraZeneca, rendendolo il mercato più grande dell'azienda con 17.800 dipendenti in 17 siti in 12 stati.
AstraZeneca anuncia una inversión de capital de 3,5 mil millones de dólares en Estados Unidos para expandir su presencia en investigación y fabricación para 2026. La inversión incluye 2 mil millones de dólares de nuevos fondos que generarán más de 1,000 empleos altamente calificados. La expansión abarca un nuevo centro de I+D en Cambridge, Massachusetts, fabricación de biológicos en Maryland, instalaciones de terapia celular en ambas costas y fabricación especializada en Texas. Esta inversión es parte de la estrategia de AstraZeneca para alcanzar 80 mil millones de dólares en ingresos totales para 2030. Actualmente, Estados Unidos representa el 44% de los ingresos totales de AstraZeneca, lo que lo convierte en el mayor mercado de la compañía con 17,800 empleados en 17 sitios en 12 estados.
아스트라제네카는 2026년까지 연구 및 제조 기반을 확장하기 위해 미국에 35억 달러의 자본 투자를 발표했습니다. 이 투자에는 1,000개 이상의 고급 일자리를 창출할 20억 달러의 새로운 자금이 포함됩니다. 확장은 매사추세츠주 케임브리지에 새로운 R&D 센터, 메릴랜드의 생물학 제조, 두 해안의 세포 치료 시설, 텍사스의 전문 제조를 포함합니다. 이 투자는 아스트라제네카가 2030년까지 800억 달러의 총 수익을 달성하기 위한 전략의 일환입니다. 현재 미국은 아스트라제네카의 총 수익의 44%를 차지하며, 12개 주의 17개 사이트에 17,800명의 직원을 두고 있는 회사의 최대 시장입니다.
AstraZeneca annonce un investissement en capital de 3,5 milliards de dollars aux États-Unis pour étendre sa recherche et sa capacité de fabrication d'ici 2026. Cet investissement comprend 2 milliards de dollars de nouveaux fonds qui créeront plus de 1 000 emplois qualifiés. L'expansion comprend un nouveau centre de R&D à Cambridge, Massachusetts, la fabrication de produits biologiques dans le Maryland, des installations de thérapie cellulaire sur les deux côtes et une fabrication spécialisée au Texas. Cet investissement fait partie de la stratégie d'AstraZeneca visant à atteindre 80 milliards de dollars de chiffre d'affaires total d'ici 2030. Les États-Unis représentent actuellement 44 % du chiffre d'affaires total d'AstraZeneca, ce qui en fait le plus grand marché de l'entreprise avec 17 800 employés répartis sur 17 sites dans 12 états.
AstraZeneca kündigt eine Kapitalinvestition von 3,5 Milliarden Dollar in den Vereinigten Staaten an, um bis 2026 seine Forschung und Produktionskapazitäten auszubauen. Die Investition umfasst 2 Milliarden Dollar an neuen Mitteln, die über 1.000 hochqualifizierte Arbeitsplätze schaffen werden. Die Erweiterung umfasst ein neues F&E-Zentrum in Cambridge, Massachusetts, die Herstellung von Biologika in Maryland, Zelltherapieeinrichtungen an beiden Küsten und Spezialherstellung in Texas. Diese Investition ist Teil von AstraZenecas Strategie, bis 2030 80 Milliarden Dollar Gesamterlös zu erzielen. Die USA machen derzeit 44 % von AstraZenecas Gesamterlös aus und sind damit der größte Markt des Unternehmens mit 17.800 Mitarbeitern an 17 Standorten in 12 Bundesstaaten.
- $3.5B investment in US operations expanding R&D and manufacturing capacity
- Creation of 1,000+ new high-skilled jobs
- Strategic expansion in largest market (US represents 44% of total revenue)
- Clear growth strategy targeting $80B in total revenue by 2030
- None.
Insights
The
The investment strategy is well-diversified across R&D and manufacturing facilities, targeting high-growth areas like biologics and cell therapy. The geographical spread from East to West Coast, combined with the creation of over 1,000 high-skilled jobs, indicates a comprehensive approach to strengthening their U.S. market position. The focus on Kendall Square, a premier biotech hub, particularly enhances their competitive positioning in innovation-driven drug development.
The strategic placement of new facilities demonstrates AstraZeneca's commitment to advancing their biologics and cell therapy capabilities. The dual-coast cell therapy manufacturing presence is particularly noteworthy, as it positions them to better serve the rapidly growing personalized medicine market. The investment in a next-generation biologics facility in Maryland indicates a strong push into complex biological drugs, which typically command higher margins and face less generic competition.
The Kendall Square R&D center location is especially strategic, placing AstraZeneca in the heart of the world's leading biotech ecosystem, facilitating collaboration with top academic institutions and biotech startups. This comprehensive infrastructure expansion will significantly enhance their ability to accelerate drug development timelines and maintain competitive advantages in key therapeutic areas.
AstraZeneca’s expanding footprint in the US includes, among others:
-
A state-of-the-art R&D centre in Kendall Square,
Cambridge, Massachusetts -
A next generation manufacturing facility for biologics in
Maryland - Cell therapy manufacturing capacity on the West and East Coasts
-
Specialty manufacturing in
Texas
Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in
Delivering growth: Ambition 2030
These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve
AstraZeneca in the US
AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning 12 states.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
- As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at: https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html. Accessed November 2024.
Adrian
Company Secretary
AstraZeneca PLC
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111540981/en/
Global Media Relations team
global-mediateam@astrazeneca.com
+44 (0)1223 344 800
Source: AstraZeneca
FAQ
How much is AstraZeneca (AZN) investing in US operations by 2026?
How many jobs will AstraZeneca's (AZN) new US investment create?
What is AstraZeneca's (AZN) revenue target for 2030?
What percentage of AstraZeneca's (AZN) revenue comes from the US market?
